A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems

Phase 3

Completed

• Conditions: HIV Infections; Chickenpox

• Registration Number: NCT00002315
• Lead Sponsor: Glaxo Wellcome

Brief Summary

To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.

Detailed Description

Patients are randomized to receive either 882C87 or acyclovir with corresponding placebos for 14 days, with two hundred patients in each of the two groups. They are stratified by presence or absence of HIV infection. Patients undergo 6 months of follow-up.

Study Timeline

• Status Verified: 1994-05
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (25)

Simon - Williamson Clinic; 🇺🇸 Birmingham, Alabama, United States

SORRA / NC Research Ctr; 🇺🇸 Birmingham, Alabama, United States

Univ of Arizona / Univ Med Ctr; 🇺🇸 Tucson, Arizona, United States

Cedars Sinai Med Ctr; 🇺🇸 Los Angeles, California, United States

AIDS Community Research Consortium; 🇺🇸 Redwood City, California, United States

Saint Francis Mem Hosp; 🇺🇸 San Francisco, California, United States

Sunnyvale Med Clinic; 🇺🇸 Sunnyvale, California, United States

Clinical Research Consultants; 🇺🇸 Trumbull, Connecticut, United States

Med Associates Clinic; 🇺🇸 Dubuque, Iowa, United States

Oschner Clinic; 🇺🇸 New Orleans, Louisiana, United States

Scroll for more (15 remaining)